299. Cystic fibrosis Clinical trials / Disease details

Clinical trials : 1,696 / Drugs : 1,644 - (DrugBank : 272) / Drug target genes : 96 - Drug target pathways : 170

2 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT01684410 (ClinicalTrials.gov)	August 2012	6/9/2012	Safety and Tolerability Trial of Inhaled Alpha1-Proteinase Inhibitor (Human), Hydrophobic Chromatography Process (Alpha-1 HC) in Subjects With Cystic Fibrosis	A Three Week Dose Escalation, Randomized, Double-Blind, Placebo-Controlled Trial to Assess the Safety and Tolerability of 100 mg or 200 mg of Inhaled Alpha-1 HC, Once a Day in Subjects With Cystic Fibrosis.	Cystic Fibrosis	Biological: Alpha-1 HC 100 mg;Biological: Placebo;Biological: Alpha-1 HC 200 mg	Grifols Therapeutics Inc.	NULL	Completed	18 Years	N/A	All	30	Phase 2	United States
2	NCT00486837 (ClinicalTrials.gov)	December 2003	13/6/2007	Deposition of Inhaled Prolastin in Cystic Fibrosis Patients	Multicenter, Randomized, Parallel Group Study to Investigate the Optimal Deposition Site for Inhaled Prolastin® in Patients With Cystic Fibrosis (CF)	Cystic Fibrosis	Drug: Alpha1-Proteinase Inhibitor (Human)	Grifols Therapeutics Inc.	NULL	Completed	8 Years	N/A	All	72	Phase 2	NULL